Cyprotex reports successful customer validation studies for Cloe Technology
Trials of Cyprotex's Cloe PK software applied to more than 150 potential drugs provided by seven pharmaceutical companies have been successful, the company says.
Trials of Cyprotex's Cloe PK software applied to more than 150 potential drugs provided by seven pharmaceutical companies have been successful, the company says.
The trials showed that Cloe PK can estimate how long a drug stays in the body and is sufficiently accurate to be used in the rapid selection of promising compounds and the early elimination of those likely to fail.
In parallel, blind trials of the Cloe Screen experimental testing technology on several hundred compounds provided by six laboratories from major pharmaceutical companies all demonstrated a high degree of accuracy.
The Cloe technology can be used to predict what would happen in humans as well as in rats, and the cumulated data showed that the Cloe technology allowed the estimation of human outcomes more accurately than experiments carried out in live rats. These results demonstrate that customers can confidently use the technology to reduce the number of animals they use in drug discovery research, while improving the chance that their drug would work in humans.
Dr David Leahy, chief scientific officer and founder of Cyprotex, said: 'Our skilled team of scientists and engineers have delivered, in less than 18 months, uniquely accurate and cost-effective technology for the estimation of pharmacokinetics. We now have the evidence that demonstrates to potential partners that the Cloe technology can improve productivity in drug discovery. We are able to offer to our partners similar information to that obtained in a Phase One clinical trial on every compound they synthesise, at a fraction of the cost, within days rather than years.'